Here's Why You Should Add ARQT Stock to Your Portfolio Now
Arcutis raises its 2026 revenue guidance as Zoryve gains momentum, expands into younger patients and advances potential new indications.
Zacks
Gilead Wins FDA Nod for Bixlenvo in Adults Living With HIV Infection
GILD wins FDA approval for Bixlenvo, a once-daily HIV regimen offering a smaller single-tablet option for patients on complex therapies.
Zacks
Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced the appointment of Darlene Deptula-Hicks to Aldeyras board of directors (the Board). Ms. Deptula-Hicks...
Business Wire
Aldeyra Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside...
Business Wire
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. (Aldeyra or the Company) (NASDAQ: ALDX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder...
Business Wire
ALDX FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aldeyra Therapeutics, Inc. (Aldeyra or the Company) (NASDAQ: ALDX) and reminds investors of the May 29, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that...
Business Wire
ALDX Deadline Tomorrow: ALDX Investors with Losses in Excess of $100K Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm
ALDX Deadline Tomorrow: ALDX Investors with Losses in Excess of $100K Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm ALDX Deadline Tomorrow: ALDX Investors with Losses in Excess of $100K Have Opportunity to Lead Aldeyra Therapeutics, Inc...
PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines - ALDX
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines - ALDX INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action...
PR Newswire
Aldeyra Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ALDX
Aldeyra Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ALDX Aldeyra Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ALDX PR Newswire LOS ANGELES, May 27, 2026 LOS ANGELES, May 27...
PR Newswire
ALDX Shareholder Alert: Aldeyra Therapeutics, Inc. Securities Class Action Lawsuit - Investors Should Contact The Gross Law Firm
ALDX Shareholder Alert: Aldeyra Therapeutics, Inc. Securities Class Action Lawsuit - Investors Should Contact The Gross Law Firm ALDX Shareholder Alert: Aldeyra Therapeutics, Inc. Securities Class Action Lawsuit - Investors Should Contact The Gross Law Firm PR Newswire NEW YORK, May 26, 2026 NEW...
PR Newswire